Crisil Reaffirms A1+ Rating on Sudarshan Chemical Industries' Rs. 50 Crore Commercial Paper Programme
Crisil has reaffirmed its 'A1+' rating on Sudarshan Chemical Industries' Rs. 50 crore commercial paper programme, citing the company's strong liquidity position of Rs. 750-850 crore and established market presence. The rating reflects confidence despite integration challenges from the Heubach group acquisition completed in March 2025 for €151.9 million. While the legacy business maintains stable margins at 12.8%, the acquired operations show declining performance with sequential revenue drops and margin pressures, making successful turnaround execution critical for sustained credit profile.

*this image is generated using AI for illustrative purposes only.
Sudarshan Chemical Industries Limited has received a reaffirmation of its 'Crisil A1+' rating on its Rs. 50 crore commercial paper programme from Crisil, an S&P Global Company. The rating agency announced this decision on April 16, 2026, maintaining its positive assessment of the company's short-term creditworthiness.
Rating Rationale and Key Strengths
The reaffirmation reflects Crisil's expectation that Sudarshan Chemical will maintain a sizeable corpus of unencumbered liquidity of Rs. 750-850 crore over the medium term. This liquidity buffer is considered crucial during the turnaround phase of the recently acquired Heubach group, ensuring timely availability of funds for business operations and debt repayment obligations.
| Rating Parameter | Details |
|---|---|
| Commercial Paper Size | Rs. 50 Crore |
| Previous Rating | Crisil A1+ |
| Revised Rating | Crisil A1+ |
| Rating Action | Reaffirmed |
The rating continues to reflect several key strengths including the extensive experience of promoters in the pigment industry, established market position of both SCIL and Heubach, diversified product range and end-user industry profile, strong distribution network with marquee clientele, and average financial risk profile supported by healthy financial flexibility.
Heubach Acquisition Impact
On March 03, 2025, SCIL completed the acquisition of Heubach group for a purchase consideration of €151.9 million (approximately Rs. 1,389.9 crore). The acquisition was funded through debt of around Rs. 1,600 crore (€175 million) and equity raise of around Rs. 1,000 crore through QIP, preferential equity issuance, and convertible warrants.
| Financial Performance | Nine Months FY26 | Nine Months FY25 | Change |
|---|---|---|---|
| Legacy Business Revenue | Rs. 1,988 crore | Rs. 1,996 crore | Largely flat |
| Acquired Group Revenue | Rs. 5,045 crore | - | New addition |
| Total Consolidated Revenue | Rs. 6,997 crore | Rs. 1,996 crore | Significant increase |
| Consolidated PAT | Loss of Rs. 42 crore | Profit of Rs. 60 crore | Negative impact |
Post-acquisition, Sudarshan Europe B.V., a wholly-owned subsidiary of SCIL, has indirectly acquired 54.36% shareholding in Heubach Colorants India Limited, which is listed on BSE and NSE. The combined entity now operates 19 manufacturing sites across 11 countries, making SCIL the second-largest pigments player globally behind DIC.
Financial Performance and Challenges
The acquired Heubach group has shown sequential revenue decline over three quarters of fiscal 2026, dropping from Rs. 1,882 crore in Q1 to Rs. 1,479 crore in Q3. This decline is attributed to demand softness in Europe and North America, coupled with inventory destocking by key customers.
Operating margins present a mixed picture. While the legacy business maintained stable margins at 12.8% in the first nine months of fiscal 2026 compared to 12.7% in the corresponding period of fiscal 2025, the acquired group's margins deteriorated significantly from 4.1% in Q1 FY26 to losses in Q3 FY26.
| Key Financial Metrics | As of/for Period |
|---|---|
| Adjusted Networth | Rs. 2,535 crore (Sept 30, 2025) |
| Total Gross Debt | Rs. 2,528 crore |
| Adjusted Gearing | 0.9 times |
| Interest Coverage | 3.2 times (9M FY26) vs 9.78 times (9M FY25) |
| Net Debt/EBITDA | 2.22 times |
| Unencumbered Liquidity | Rs. 1,097 crore (Dec 31, 2025) |
Liquidity Position and Outlook
Crisil has assessed the company's liquidity as 'Strong', highlighting the unencumbered liquid surplus of Rs. 1,097 crore as of December 31, 2025. The rating agency expects annual net cash accrual of Rs. 250-350 crore along with cash surplus of Rs. 750-850 crore to be sufficient for meeting yearly debt repayment obligations of Rs. 120-300 crore and annual capital expenditure of Rs. 150-250 crore over the next two years.
The company also maintains access to fund-based limits of Rs. 515 crore with an average 12-month drawing power of Rs. 333 crore, which has been utilized to 69% on average during the past 12 months through January 2026.
Strategic Transformation
The Heubach acquisition has significantly transformed SCIL's global footprint and product portfolio. The company now offers approximately 1,600+ products across 60+ brands, with market reach extending to around 120 countries from the previous 85 countries. The acquisition provides access to coatings, plastics, and inks segments in overseas markets with an established customer base.
While the rating reaffirmation indicates confidence in the company's fundamental strengths and liquidity position, Crisil notes that the successful execution of the turnaround strategy for the Heubach operations will be critical for maintaining the current credit risk profile and achieving improved profitability metrics over the medium term.
Historical Stock Returns for Sudarshan Chemical Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.71% | +2.22% | +15.10% | -25.31% | -18.34% | +61.19% |
What specific turnaround strategies will Sudarshan Chemical implement to reverse Heubach's declining margins and sequential revenue drops?
How might the ongoing demand softness in Europe and North America affect Sudarshan's ability to maintain its projected cash accruals of Rs. 250-350 crore annually?
Will Sudarshan Chemical consider divesting underperforming Heubach assets if the turnaround doesn't materialize within the expected timeframe?


































